// App-Quantinova.ai

THU0215 : WHOLE BLOOD TRANSCRIPTIONAL CHANGES FOLLOWING SELECTIVE INHIBITION OF JANUS KINASE 1 (JAK1) BY FILGOTINIB IN ADULTS WITH MODERATELY-TO-SEVERELY ACTIVE RHEUMATOID ARTHRITIS WITH PRIOR INADEQUATE RESPONSE TO METHOTREXATE (FINCH1)

Researchers

Presenter

  • P. C. Taylor

Principal Investigators

  • B. Downie

  • E. Elboudwarej

  • S. Kim

  • A. Hertz

  • A. M. Mirza

  • J. Siegel

  • R. E. Hawtin

  • J. Liu

Medical Centers

  • University of Oxford, Botnar Research Centre, Nuffield Dept Orthopaedics, Rheumatology and Musculoskeletal Sciences, Oxford, United Kingdom

  • 1.Gilead Science Inc, Foster City, United States of America

Locations

  • United Kingdom

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Autoimmune (AI)

Disease

  • Rheumatoid arthritis

Biomarkers

  • N/A

Drug/Treatment

  • Methotrexate

  • Adalimumab

  • Filgotinib

Outcome

  • N/A

Study Design

  • Randomized

  • Placebo Control

Phase

  • III

Study Id's

  • NCT02889796

Sponsors

  • Gilead Sciences

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved